[go: up one dir, main page]

WO2005050203A3 - The methods for screening using ctgf and trka receptor for the identification of compounds for use in treatment of fibrosis - Google Patents

The methods for screening using ctgf and trka receptor for the identification of compounds for use in treatment of fibrosis Download PDF

Info

Publication number
WO2005050203A3
WO2005050203A3 PCT/GB2004/004795 GB2004004795W WO2005050203A3 WO 2005050203 A3 WO2005050203 A3 WO 2005050203A3 GB 2004004795 W GB2004004795 W GB 2004004795W WO 2005050203 A3 WO2005050203 A3 WO 2005050203A3
Authority
WO
WIPO (PCT)
Prior art keywords
ctgf
ctgf receptor
compounds
fibrosis
test sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2004/004795
Other languages
French (fr)
Other versions
WO2005050203A2 (en
Inventor
Roger Maxwell Mason
Nadia Abdel Wahab
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ip2ipo Innovations Ltd
Original Assignee
Imperial College Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial College Innovations Ltd filed Critical Imperial College Innovations Ltd
Priority to EP04798515A priority Critical patent/EP1718979A2/en
Priority to JP2006540577A priority patent/JP2007515162A/en
Priority to CA002546401A priority patent/CA2546401A1/en
Priority to AU2004292013A priority patent/AU2004292013A1/en
Publication of WO2005050203A2 publication Critical patent/WO2005050203A2/en
Publication of WO2005050203A3 publication Critical patent/WO2005050203A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Dermatology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

The invention provides a method for identifying and/or making compounds for use in reducing and/or preventing fibrosis, comprising the steps: providing a CTGF receptor; providing a test sample; providing a CTGF receptor agonist; exposing the CTGF receptor to the test sample; subsequently or simultaneously exposing the CTGF receptor to the CTGF receptor agonist; detecting and/or measuring the amount of CTGF receptor activation; comparing the amount of CTGF receptor activation detected and/or measured in the presence of the test sample with the amount of CTGF receptor activation detected and/or measured in the absence of a test sample; determining if a compound reduces and/or prevents fibrosis on the basis that it causes no increase or a decrease in CTGF receptor activation. There is also provided compounds for reducing and/or preventing fibrosis and uses of such compounds.
PCT/GB2004/004795 2003-11-18 2004-11-15 The methods for screening using ctgf and trka receptor for the identification of compounds for use in treatment of fibrosis Ceased WO2005050203A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP04798515A EP1718979A2 (en) 2003-11-18 2004-11-15 Methods of screening using ctgf and trka receptor for the identification of compounds for use in treatment of fibrosis
JP2006540577A JP2007515162A (en) 2003-11-18 2004-11-15 Screening method using CTGF and TRKA receptors for the identification of compounds used in the treatment of fibrosis
CA002546401A CA2546401A1 (en) 2003-11-18 2004-11-15 The methods for screening using ctgf and trka receptor for the identification of compounds for use in treatment of fibrosis
AU2004292013A AU2004292013A1 (en) 2003-11-18 2004-11-15 Methods for screening using CTGF and TRKA receptor for the identification of compounds for use in treatment of fibrosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0326780.4 2003-11-18
GBGB0326780.4A GB0326780D0 (en) 2003-11-18 2003-11-18 Biological materials and uses thereof

Publications (2)

Publication Number Publication Date
WO2005050203A2 WO2005050203A2 (en) 2005-06-02
WO2005050203A3 true WO2005050203A3 (en) 2005-11-17

Family

ID=29763971

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/004795 Ceased WO2005050203A2 (en) 2003-11-18 2004-11-15 The methods for screening using ctgf and trka receptor for the identification of compounds for use in treatment of fibrosis

Country Status (7)

Country Link
EP (1) EP1718979A2 (en)
JP (1) JP2007515162A (en)
CN (1) CN1906491A (en)
AU (1) AU2004292013A1 (en)
CA (1) CA2546401A1 (en)
GB (1) GB0326780D0 (en)
WO (1) WO2005050203A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9688987B2 (en) 2008-08-25 2017-06-27 Excaliard Pharmaceuticals, Inc. Antisense oligonucleotides directed against connective tissue growth factor and uses thereof

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0326778D0 (en) * 2003-11-18 2003-12-24 Imp College Innovations Ltd Biological materials and uses thereof
US20060275797A1 (en) * 2005-03-21 2006-12-07 Alcon Manufacturing, Ltd. Use of agents which inhibit connective tissue growth factor (CTGF) binding and signaling via the TrkA/p75NTR receptor complex for the prevention and treatment of CTGF-mediated ocular disorders
US8946172B2 (en) 2008-08-25 2015-02-03 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to CTGF
EP2169059A1 (en) * 2008-09-25 2010-03-31 Academisch Medisch Centrum bij de Universiteit van Amsterdam Means and methods for counteracting, preventing and/or determining fibrosis or a risk of fibrosis
EP2221387A1 (en) 2009-02-19 2010-08-25 Université de la Méditerranée Fibrosis susceptibility gene and uses thereof
MX365647B (en) 2011-02-02 2019-06-10 Excaliard Pharmaceuticals Inc Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (ctgf).
DK2739748T3 (en) 2011-08-05 2019-06-24 Univ Aix Marseille IL22RA2 GEN WITH FIBROSE SENSITIVITY AND USE THEREOF
KR101467109B1 (en) * 2013-07-10 2014-12-01 영남대학교 산학협력단 Composition for preventing or treating pulmonary fibrosis comprising BIX02189 compound
ES2874533T3 (en) 2014-02-05 2021-11-05 VM Oncology LLC Compositions of compounds and their uses
TW201639573A (en) * 2015-02-03 2016-11-16 吉李德科學股份有限公司 Combination therapies for treating cancers
AU2020281378B2 (en) * 2019-05-30 2025-09-11 Sunshine Lake Pharma Co., Ltd. Anti-TrkA antibodies and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555322B1 (en) * 1999-08-27 2003-04-29 Fibrogen, Inc. α2-macroglobulin receptor as a receptor for CTGF

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555322B1 (en) * 1999-08-27 2003-04-29 Fibrogen, Inc. α2-macroglobulin receptor as a receptor for CTGF

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 2000, WONG S T ET AL: "Treatment for autonomic dysreflexia using trkA-IgG after spinal cord injury", XP002336070, Database accession no. PREV200100135018 *
LEASK ANDREW ET AL: "Insights into the molecular mechanism of chronic fibrosis: The role of connective tissue growth factor in scleroderma.", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 122, no. 1, January 2004 (2004-01-01), pages 1 - 6, XP008049522, ISSN: 0022-202X *
POLLOCK GRAEME S ET AL: "TrkB receptor signaling regulates developmental death dynamics, but not final number, of retinal ganglion cells.", JOURNAL OF NEUROSCIENCE, vol. 23, no. 31, 5 November 2003 (2003-11-05), pages 10137 - 10145, XP002335976, ISSN: 0270-6474 *
RACHFAL AMY W ET AL: "Connective tissue growth factor (CTGF/CCN2) in hepatic fibrosis.", HEPATOLOGY RESEARCH, vol. 26, no. 1, May 2003 (2003-05-01), pages 1 - 9, XP002335977, ISSN: 1386-6346 *
SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 26, no. 1-2, 2000, 30TH ANNUAL MEETING OF THE SOCIETY OF NEUROSCIENCE; NEW ORLEANS, LA, USA; NOVEMBER 04-09, 2000, pages Abstract No. - 864.4, ISSN: 0190-5295 *
WAHAB NADIA ABDEL ET AL: "Connective tissue growth factor CCN2 interacts with and activates the tyrosine kinase receptor TrkA", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 16, no. 2, February 2005 (2005-02-01), pages 340 - 351, XP008049530, ISSN: 1046-6673 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9688987B2 (en) 2008-08-25 2017-06-27 Excaliard Pharmaceuticals, Inc. Antisense oligonucleotides directed against connective tissue growth factor and uses thereof

Also Published As

Publication number Publication date
CN1906491A (en) 2007-01-31
WO2005050203A2 (en) 2005-06-02
GB0326780D0 (en) 2003-12-24
EP1718979A2 (en) 2006-11-08
JP2007515162A (en) 2007-06-14
CA2546401A1 (en) 2005-06-02
AU2004292013A1 (en) 2005-06-02

Similar Documents

Publication Publication Date Title
IL181131A0 (en) USE OF C3a AND DERIVATIVES THEREOF AS A BIOMARKER FOR COLORECTAL ADEMONA AND/OR CARCINOMA; DIAGNOSIS METHOD AND TEST SYSTEM USING THE SAME
WO2003043487A3 (en) Method of using a non-antibody protein to detect and measure an analyte
WO2005041893A3 (en) Detection of acute myocardial infarction biomarkers
WO2003016527A3 (en) Process for the detection of oxidative stress and kit for its implementation
WO2005050203A3 (en) The methods for screening using ctgf and trka receptor for the identification of compounds for use in treatment of fibrosis
WO2007079344A3 (en) Methods and systems for binning defects detected on a specimen
WO2006089027A3 (en) Lateral flow test kit and method for detecting an analyte
EP1957989A4 (en) DEVICE FOR DETECTING THE PRESENCE OR QUANTITY OF AN ANALYTE IN A FLUID SAMPLE, AND ASSOCIATED METHOD
WO2003046531A3 (en) Method for detecting defects in substrates
WO2008109075A3 (en) Biomarkers and methods for determining sensitivity to ctla-4 antagonists
WO2009028062A1 (en) Fret detection method and device
WO2004013610A3 (en) Method of measuring molecular interactions
WO2005031005A3 (en) Compositions, methods and kits for determining the presence of trichomonas vaginalis in a test sample
WO2004057336A3 (en) Use of nicotinamide n-methyltransferase as a marker for colorectal cancer
WO2008063663A3 (en) Poly (ethylene glycol) anti-body detection assays and kits for performing thereof
WO2003057014A3 (en) Biomarkers for detecting ovarian cancer
EP1652676A3 (en) Systems and methods for detecting inkjet defects
WO2003102015A3 (en) Method and apparatus for detecting and monitoring peptides, and peptides identified therewith
EP1586900A3 (en) Methods for identifying combinations of entities as therapeutics
WO2005081783A3 (en) Method for determination and quantification of radiation or genotoxin exposure
WO2004087622A3 (en) Gpr54 receptor agonist and antagonist useful for the treatmentt of gonadotropin related diseases
WO2005119209A3 (en) System and method for analyzing microbial growth
WO2001083816A3 (en) Method for detecting tumors
WO2004092730A3 (en) Method and device for detecting the presence of an analyte
WO2007061940A3 (en) Method for detecting an inflammatory disease or cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2546401

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 547296

Country of ref document: NZ

Ref document number: 2006540577

Country of ref document: JP

Ref document number: 2827/DELNP/2006

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2004292013

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004798515

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004292013

Country of ref document: AU

Date of ref document: 20041115

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004292013

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200480040637.8

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2004798515

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2004798515

Country of ref document: EP